TGFB1 and Miyoshi myopathy: TGFβ is not likely to have the same effect here since TGFβ signaling is typically antagonized by FGF signaling through the ERK/MAPK pathway [71]–[73], and, in the case of MM cells, malignant cells express fewer surface receptors and are resistant to TGFβ signaling [74]–[77].